Skip to main content
Premium Trial:

Request an Annual Quote

Newfound Genomics Inks Dx Deals with Genesis Group, PGxHealth

NEW YORK (GenomeWeb News) – Newfound Genomics, a genetic research and genotyping services firm based in St. Johns, Newfoundland, today said that it has signed a memorandum of understanding with the Genesis Group that provides Newfound with the opportunity to commercialize certain discoveries from Memorial University in the field of human genetics.
 
Genesis Group is the commercialization arm of the university, where Newfound CEO Wayne Gulliver is a professor of medicine and dermatology. The tech transfer group also inked a second pact with Newfound that provides the firm with certain exclusive rights to develop and market a test for arrhythmogenic right ventricular cardiomyopathy.
 
Concurrent with that pact, Newfound granted an exclusive sub-license to Clinical Data’s PGxHealth unit to perform and market a test to diagnose AVRC in the US, Europe, and certain other undisclosed territories.
 
Gulliver said that Newfound “will be making this test available in a matter of weeks.”
 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.